AXL and neoplasm: An ADC comprised of an AXL antibody conjugated to an antimitotic drug blocked tumor growth in vitro and in vivo in treatment-naïve and targeted therapy-resistant CM, and these effects were enhanced upon the addition of BRAFi and MEKi (Boshuizen et al., 2018).